enVVeno Medical Corporation (NASDAQ:NVNO – Get Free Report) was the recipient of a large growth in short interest in the month of October. As of October 30th, there was short interest totaling 24,103 shares, a growth of 104.8% from the October 15th total of 11,771 shares. Approximately 4.1% of the company’s shares are short sold. Based on an average trading volume of 39,897 shares, the short-interest ratio is currently 0.6 days.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of enVVeno Medical in a research note on Friday, September 25th. Wall Street Zen downgraded enVVeno Medical from a “hold” rating to a “sell” rating in a research report on Sunday, November 1st. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.
enVVeno Medical Trading Down 3.6%
Shares of NASDAQ NVNO traded down $0.22 on Monday, reaching $5.95. 12,092 shares of the company traded hands, compared to its average volume of 20,943. The stock has a market capitalization of $4.11 million, a PE ratio of -0.34 and a beta of 1.41. enVVeno Medical has a fifty-two week low of $5.80 and a fifty-two week high of $14.66. The company has a 50 day moving average of $8.11 and a 200 day moving average of $10.09.
enVVeno Medical (NASDAQ:NVNO – Get Free Report) last released its earnings results on Thursday, October 29th. The company reported ($6.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.27) by ($3.02). As a group, research analysts expect that enVVeno Medical will post -16.19 earnings per share for the current year.
About enVVeno Medical
enVVeno Medical is a medical-device company developing treatments for chronic venous disease, with a focus on deep venous chronic venous insufficiency. This condition can occur when valves in the leg’s deep veins do not function properly, impairing blood flow back to the heart. The company’s lead product, VenoValve, is a bioprosthetic valve designed to restore valve function in affected deep veins. enVVeno has also described a transcatheter valve program, enVVe, intended to provide a less invasive approach to treating the condition.
Recommended Stories
- Five stocks we like better than enVVeno Medical
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for enVVeno Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enVVeno Medical and related companies with MarketBeat.com's FREE daily email newsletter.
